The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Interesting find CW/chilltime.
I found the job link:
https://genmab.wd3.myworkdayjobs.com/en-US/Genmab_Careers_Site/job/Director--Patent-Attorney_R10059
I found these job requirements interesting, though not fully understanding the implications?
"... Your job will include preparing IP strategies, drafting and prosecuting patent applications, reviewing documents prior to publication, ***evaluating third party patent rights***"
"Survey third party patent positions, file relevant actions, and solicit legal opinions against third party patent rights."
Thanks CW, Should help Scancell receive proper notice. IMO
Looks like Genmab beefing up legal teams in USA .
Their KYO time line seems to be working
We also know close relationship with Scancell noted LD was tight lipped
Good posts this morning from
Chill time over on the other side
From jobs
https://www.goinhouse.com
After it announced this week
Director, Legal Counsel (US Market Operations)
* Genmab
* Princeton, NJ
Apr 23
* Director, Patent Attorney
* Genmab
* Princeton, NJ
Apr 15
Recent Genmab news
May 2, 2024 at 5:02 PM CEST
Genmab Announces Financial Results for the First Quarter of 2024
Download
Apr 30, 2024 at 12:40 AM CEST
TIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervical Cancer
Apr 29, 2024 at 10:24 AM CEST
Transactions in Connection with Share Buy-back Program Genmab
Download
Download
Kate Bingham tells NHS to launch experimental cancer vaccine trials with pioneering technology that trains the immune system how to hunt malignant cells
https://www.dailymail.co.uk/health/article-13383755/Former-Covid-jab-tsar-tells-NHS-launch-experimental-cancer-vaccine-trials-pioneering-technology-trains-immune-hunt-malignant-cells.html
“Dr Lennard Lee, a cancer vaccine expert at the University of Oxford, said there are now 12 drug manufacturers testing cancer jabs in the UK. He added: 'We are already gaining the reputation as the best country in the world to develop cancer vaccines.'
This was a post on linked in from a month ago
Robert Watson
•
Clinical Lecturer, University of Oxford | Oncologist | Physician Scientist | Tumour Immunologist
Clinical Lecturer, University of Oxford | Oncologist | Physician Scientist | Tumour Immunologist
1mo •
From a month ago F
Fascinating to attend an investigator meeting for Scancell Ltd's SCOPE study - the second meeting for a
hashtag
#cancervaccine clinical trial in melanoma that I've been to in the space of a few weeks. Great to hear about the immunology underpinning the therapy and enjoyable to interact with other trial teams around the UK. It is really fantastic to be able to offer these cutting-edge clinical trials to our patients at Oxford University Hospitals NHS Foundation Trust and see such rapid ongoing progress in the cancer vaccine space.
Also on Tiktok now too:
https://www.tiktok.com/@biotechtv/video/7365101459177950510
From the Interview the very least Sclp should get Is the deserved exposure for the variety and successful Trials results they have achieved. IMO
I would prefer a substantial RNS on Tuesday…..
If the aim is to get as much coverage as possible, a good starting point would be for Scancell themselves to retweet.
Agreed but the twitter video is very short compared to the full BioTech TV channel.
Maybe both links is the answer.
Just IMO if you're going to watch/share the video it's better to click/share the twitter link as it ticks the social media/YouTube boxes in one go.
Having just read the article posted in the times . its interesting the derisory share price of Scancell , will hopefully be a thing of the past when data arrives
It takes an American Biotech expert to showcase the company and a very confident Lindy Durrant
we just need more "patience and patients" to put the data forward
Hi Burble
Yes that’s the one. The first mention was months ago and I would suspect the necessary forms had already been sent in.
These things don’t happen overnight but there should have been enough time for an NHS decision to be close.
If my mind serves me correctly, didn’t LD say that they may look to go for renal cell carcinoma with doublet checkpoint therapy with modi-1?
RCC currently can have nivolumab (Opdivo) with ipilimumab (Yervoy) as front line treatment. So similar to SCIB1 in melanoma.
During the interview LD says that they hope to trial Modi1 with a duplex of CPI’s.
I cannot remember which cancer indication that is in. What we do know is that it will be an NHS approved double checkpoint and we are looking to start a new cohort in that indication as part of an expanded ModiFY Trial.
This has been hinted at before so we can add that to the anticipated news list.
Another possible news item is in the ModiFY Renal cohort. Currently the patients we can enroll Modi1 is approved as a third line treatment and due good results we have applied to move that up to a first line treatment. I would imagine that would lead to much faster recruitment in that Cohort.
Good morning
positive interview and a confident Lindy Durant
1 the new improved vaccine it’s going to mean that it’s available for everybody . More people all types (4 already ) so fast into the clinic bigger numbers .does that translate into Fast track approval!
2 Madonna as being personalised is a juggernaut it’s expensive ,not going to be available for
3. The main listing is interesting because maybe some sort of share swop / takeover? Nasdaq in the next breath . A nod to us the long term holders AIM has been good to us
4 I think you should also listen to the prof Christian ottenmeiser 7 mins in
5. Also post re melanoma month and Scancell post on stuff coming out ? Patients on trials maybe
Christian ottenmeiser on news the day all the Moderna publicity was out ? Does anyone think this could be Moditope , moderna , scope either was his take on personal vaccines is interesting ?
8 minutes in v interesting
https://www.youtube.com/watch?v=eToDmmja2xk
Imho the ones that have left were
1 corrupt (DVRG etc)
2 burning £5mln+a year
3 were controlled by BOD/funds holding 50%+
The cream left will rise to the top in this cycle
AIM rebound
true, though, that markets run in cycles, as investors react to swings in interest rates, inflation and, like any human activity, fashion. Aim has been out of favour before and rebounded strongly. It was crushed after the 2007-08 banking crisis and fell below 400 points in February 2009. It more than doubled over the next two years. It lost a third of its value at the start of 2020 when the pandemic struck and then surged to an all-time high 18 months later.
Time, then, for another Lazarus-like recovery? Maybe.
In the past, Aim has perked up roughly in step with the main market, but it has not yet shown signs of following the FTSE 100. Is it possible that investors will not return, that the lure of technology stocks, the rise of passive investing and the dearth of small-cap fund specialists mean that Aim won’t bounce back? Richard Power, head of smaller companies at Octopus Investments, is scornful of that theory: “At the bottom of a cycle, everyone says it is different this time round. And they are always wrong.”
He is probably right. The forces that shape markets do not change that much and the pendulum will swing eventually. What might give it a push? Power and Ensor both think that interest rate cuts will reawaken investors’ appetite for risk and will send them searching in less-frequented areas of the market. If rate cuts do arrive later in the year, it could signal the start of the next Aim cycle.
Reiterating a point made by someone else on here RE lack of mention of antibodies in the interview, noticably hush hush?
"04/5/2024
11:09 You'll have noted that antibodies were glossed over.Worth remembering there are five possible deals under discussion. Maybe the first of them next week?
markingtime"
I guess lots of companies must be considering an exit from Aim....
Nicked from the HARL board
https://www.thetimes.co.uk/article/347a300d-4ae5-462a-94a4-2f42b75bd5b4?shareToken=80131960a336d5ed7ba945a063ccf029
Chelsea, interviews and posters okay call it progress.
@marcusl2 - for some reason your comment is getting the "Show additional replies, including those that may contain offensive content". Might be worth reposting it with some changes.
I’ve sent the link to Sky……………you never know.
Judging by the number of views, it looks like Brad's videos have quite a following. Great publicity for Scancell
Here is the full video as posted by bazookajr .
https://www.biotechtv.com/post/scancell-may-3-2024
Two of those were Loafas and Dracula, both of whom have accidentally on purpose hit the “Like” symbol.